Epinephrine and Umeclidinium interaction
Epinephrine and Umeclidinium: the Umeclidinium prescribing label mentions this combination without an instruction to avoid it or change the dose.
Mentioned, no instruction to avoid. Worth knowing; rarely a reason to change anything on its own.
What the FDA labels say
From the Umeclidinium (Umeclidinium Ellipta) label · effective 2025-11-06
Acute symptoms should be treated with an inhaled, short-acting beta 2 -agonist.
If Umeclidinium ELLIPTA no longer controls symptoms of bronchoconstriction; the patient’s inhaled, short-acting beta 2 -agonist becomes less effective; or the patient needs more short-acting beta 2 -agonist than usual, these may be markers of deterioration of disease.
If paradoxical bronchospasm occurs following dosing with Umeclidinium ELLIPTA, it should be treated immediately with an inhaled, short-acting bronchodilator; Umeclidinium ELLIPTA should be discontinued immediately; and alternative therapy should be instituted.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.